Respirology Search
Respirology Respirology
rhinitis%20-%20nonallergic
RHINITIS - NONALLERGIC
Nonallergic rhinitis is the inflammation of the nasal lining membranes without any immunoglobulin E mediation, as documented by allergen skin testing.
Major signs and symptoms include nasal itching, watery rhinorrhea, nasal obstruction/congestion, sneezing and postnasal drainage.
Symptoms can reverse spontaneously with or without treatment.

Rhinitis%20-%20nonallergic Patient Education

Patient Education

  • Provide general information about the disease & available treatments
    • Manage patient’s expectations from therapy & explain that a complete cure may not be possible
  • Provide educational materials as necessary
  • Educate patient about the proper use of medications & possible side effects
    • Concomitant medications should also be reviewed to determine if the patient is taking drugs that may cause oral or nasal dryness
  • Lifestyle modifications such as proper hygiene & regular nasal rinsing
    • Good personal hygiene may minimize the risk of exposure to triggers (eg viruses, environmental irritants)
    • Nasal rinsing when done properly may assist in the absorption of nasal medications; See Nasal Saline Irrigation in the Pharmacotherapy section
  • Educate patient about the complications of rhinitis (eg otitis media & chronic sinusitis)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
How to control asthma well: Experts’ perspectives
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Brensocatib tackles exacerbations in bronchiectasis
Roshini Claire Anthony, 22 Sep 2020

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.

Masitinib demonstrates potential for severe asthma
Audrey Abella, 22 Sep 2020
The first-in-class oral tyrosine kinase inhibitor (TKI) masitinib demonstrated a positive benefit-risk profile over a sustained period in patients with severe persistent asthma regardless of baseline eosinophil level, with the greatest benefit seen among those with the highest oral corticosteroid (OCS) dependency, according to data presented at ERS 2020.
Sustained-release morphine may benefit patients with COPD
Audrey Abella, 05 Oct 2020
Regular, low-dose, oral sustained-release morphine improved the health status of patients with moderate-to-very-severe chronic breathlessness due to chronic obstructive pulmonary disease (COPD), the MORDYC* trial has shown, validating its palliative role for chronic breathlessness.